Ree Labs
ReeLabs Private Limited is an India-headquartered regenerative medicine company founded in 2009 that provides stem cell banking from 10 biological sources, stem cell therapy for 80+ disorders, the DCGI-approved REEPLASTY knee treatment, and the patented Golden Vial anti-ageing program, serving over 100,000 patients and 300+ hospitals across India and internationally.
- Company typePrivate
- Founded2009
- HeadquartersMumbai, India
- Headcount101–250
- GTM typeB2C
- OfferingServices
What Ree Labs does
ReeLabs Private Limited is an India-based regenerative medicine company founded in 2009 and headquartered in Mumbai, providing stem cell banking and therapy services across a broad clinical and consumer footprint. The company collects and cryopreserves stem cells from 10 different biological sources, including umbilical cord blood, cord tissue, placenta, amniotic sac, amniotic fluid, bone marrow, adipose tissue, menstrual fluid, dental pulp, and hair follicles, positioning itself as the only Indian bank with capabilities across all 10 sources. Core technology is built around proprietary processing systems (claiming 99% cell recovery) and an exclusive UK partnership with TotiCyte, which the company states delivers 2.2-3x more stem cells at the point of therapy than competing technologies. The portfolio also includes REEPLASTY (a DCGI-approved allogenic stem cell treatment for knee osteoarthritis), a patented Golden Vial anti-ageing protocol, and biological age testing through epigenetic analysis.
Ree Labs firmographics
Firmographics- Name
- Ree Labs
- Legal name
- ReeLabs Private Limited
- Website
- https://reelabs.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- ReeLabs Private Limited is an India-headquartered regenerative medicine company founded in 2009 that provides stem cell banking from 10 biological sources, stem cell therapy for 80+ disorders, the DCGI-approved REEPLASTY knee treatment, and the patented Golden Vial anti-ageing program, serving over 100,000 patients and 300+ hospitals across India and internationally.
- Ownership category
- akta.pro rank
Ree Labs industry classification
Industry- Product category
- Stem Cell Banking Services
- NAICS
- Blood and Organ Banks (621991), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
- akta.pro secondary industries
- Stem Cell–Based Regenerative Therapies (HLAAAGAA), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Bone Marrow & Stem Cell Transplant (BMT/HSCT) (HLAKAFAI)
Keywords
Where Ree Labs is headquartered
LocationHeadquarters
- HQ city
- Mumbai
- HQ country
- India
- HQ region
- Asia
Offices6 records
Markets served
Ree Labs business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Stem Cell Banking Services: One-time collection and processing fee plus recurring annual storage fees for cryopreservation of stem cells from various biological sources (cord blood, cord tissue, placenta, amniotic fluid, amniotic sac, bone marrow, adipose tissue, menstrual fluid, dental pulp). Multiple plan options with EMI payment facilities available.
- Stem Cell Therapy Services: Treatment services using stem cells for over 80 approved disorders including leukemia, thalassemia, aplastic anemia, sickle cell anemia, osteoarthritis, cerebral palsy, muscular dystrophy, and others. Includes REEPLASTY knee treatment and various regenerative therapies.
- Golden Vial Anti-Ageing Program: Premium holistic biological age reversal program featuring young blood plasma and exosome administration. Customized for each individual with duration and dosage determined by doctors. Effects expected to last 5-10 years.
- Biological Age Testing: Comprehensive quantifiable protocol measuring all parameters related to ageing. Samples tested at US-based CLIA certified, HIPAA compliant lab. Report delivered within 2-3 weeks.
- Baby Registry Gifting Platform: Platform allowing family and friends to contribute towards stem cell banking costs as a gift. Gift registry starts at ₹1000 and multiples thereof.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | One time/ perpetual license | Baby Registry Gift Contribution |
| Subscription | Monthly | EMI Payment Option |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Ree Labs product offering
Product offeringCore offering
ReeLabs provides stem cell banking services from 10 different biological sources (umbilical cord blood, cord tissue, placenta, amniotic sac, amniotic fluid, bone marrow, adipose tissue, menstrual fluid, dental pulp, and hair follicles) along with stem cell therapy for over 80 approved disorders. The company also offers DCGI-approved REEPLASTY treatment for knee osteoarthritis, the patented Golden Vial anti-ageing program, and epigenetic biological age testing.
Product overview
Ree Labs operates as a comprehensive regenerative medicine and longevity company offering a multi-product portfolio centered on stem cell banking, therapy, and biological age assessment. The core offerings include stem cell banking services across eight tissue types (placental, umbilical cord, amniotic fluid, dental pulp, bone marrow, menstrual fluid, adipose, and cord blood via Toticyte), therapeutic applications including the DCGI-approved REEPLASTY treatment for osteoarthritis and the patented Golden Vial Anti-Ageing Program, and biological age testing via epigenetic analysis. The company extends its reach through sub-brands ReeVeda (nutraceuticals) and ReeBaby (parenting support), creating an integrated ecosystem spanning cord blood banking, anti-ageing interventions, and wellness products.
Differentiator
Problem solved
Functional benefit
Brands
- ReeVeda: Range of nutraceutical products.
- ReeBaby
- Toticyte
Products and services
- Stem Cell Banking Comprehensive stem cell banking services covering multiple tissue types including placental, umbilical cord, amniotic fluid and sac, dental pulp, bone marrow, menstrual fluid, and adipose tissue, with long-term cryogenic storage for future therapeutic use. Targeted at expecting and new parents and individuals seeking biological preservation.
- Stem Cell Therapy Therapeutic applications of stem cells for conditions including leukemia, thalassemia, osteoarthritis, cerebral palsy, and other degenerative and genetic disorders.
- REEPLASTY A DCGI-approved stem cell treatment for knee pain and osteoarthritis, utilizing mesenchymal stem cell (MSC) therapy to regenerate cartilage and reduce inflammation in joints. Procedure takes less than 30 minutes as outpatient treatment.
- Golden Vial Anti-Ageing Program A patented anti-ageing protocol featuring intravenous stem cell infusions, young blood plasma and 240 types of organ-specific exosomes, interleukins, cytokines, and growth factors. Designed to combat ageing, improve vitality, and address age-related degenerative conditions. Claims to reduce biological age by up to 20 years.
- Biological Age Testing An epigenetic testing service that measures biological age through CpG values and DNA methylation analysis from blood samples, processed at CLIA-certified US-based laboratories to determine true cellular ageing versus chronological age. Report delivered within 2-3 weeks.
- ReeVeda A nutraceutical product line offering science-backed nutritional supplements designed to support overall health, wellness, and cellular vitality.
- ReeBaby A comprehensive baby care product line including baby registry services and parenting support resources designed for expectant and new parents.
- Stem Cell Banking Baby Registry Platform allowing family and friends to contribute towards stem cell banking costs as a gift. Gift registry starts at ₹1,000 and multiples thereof.
- ReeLabs Franchise Program
Quantifiable outcome
- 2.2-3x higher stem cell recovery with TotiCyte technology
- +4 more outcomes
Companies that use Ree Labs
Customer profileNamed customers12 records
Segments5 records
Ideal customer profiles5 records
Ree Labs technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Ree Labs partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- TotiCytecorePartnership with UK-based TotiCyte brings world-class cord blood processing technology to India. TotiCyte found to be highest performing cord blood processing system in peer-reviewed head-to-head study. Delivers 2.2 to 3 times more stem cells at therapy point and removes 99% of red blood cells.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Ree Labs competitors and assessment
Company assessmentDirect peers
- LifeCell International: India's largest private stem cell and cord blood banking company, offering comparable umbilical cord, cord tissue, and peripheral blood banking plus community stem cell banking programmes. Direct competitor for the same expecting-parent segment in India.
- Cryo-Cell International: US-listed cord blood bank offering private and family cord blood banking plus menstrual stem cell banking — directly comparable business model and product set to ReeLabs' 10-source banking platform.
- ViaCord: US cord blood and cord tissue banking service owned by Revvity (formerly PerkinElmer), competing on collection quality, processing technology and storage reliability — a relevant benchmark for ReeLabs' TotiCyte-led technology story.
- Cryoviva India: Cord blood and stem cell bank operating across South and Southeast Asia, offering similar cord blood and tissue banking services plus therapy access. Directly competes with ReeLabs on Indian expecting-parent customers.
- Medipost: Korean biotech operating one of the world's largest umbilical cord blood banks (CARTISTEM) and commercialising MSC-based stem cell therapies — combining bank + therapy model that closely mirrors ReeLabs' strategic direction.
- CordLife: Asia-Pacific cord blood and tissue banking group with India operations, competing in the same umbilical cord banking category with similar subscription-based storage model and overlapping hospital channel partnerships.
Emerging players
- Novadip Biosciences: Clinical-stage cell therapy company developing autologous and allogeneic MSC-derived products for bone and skin regeneration. Comparable on the regenerative therapy positioning that REEPLASTY targets in orthopedics.
- Stempeutics Research: Bengaluru-based stem cell therapy developer focused on allogeneic MSC-based products for osteoarthritis, critical limb ischemia and other indications. Closest Indian peer on the therapy commercialisation path that ReeLabs is pursuing with REEPLASTY.
- Mesoblast: Australia-listed allogeneic MSC therapy developer with late-stage programs in inflammatory and cardiovascular indications. Comparable on the MSC-based therapy side of ReeLabs' business and a useful benchmark for therapy-stage valuations.
Regional players
- Global Cord Blood Corporation: NYSE-listed operator of cord blood banks in China (including Hong Kong). Comparable business model (subscription cord blood storage) and regional bank network, useful as a comparable for ReeLabs' Asia footprint ambitions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Ree Labs social profiles
Digital presenceRee Labs compliance and trust
Trust signalCompliance7 records
Ree Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ree Labs leadership team
Management profileNumber of profiles
Profiles1 record
Ree Labs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ree Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ree Labs
What does Ree Labs do?
ReeLabs provides stem cell banking services from 10 different biological sources (umbilical cord blood, cord tissue, placenta, amniotic sac, amniotic fluid, bone marrow, adipose tissue, menstrual fluid, dental pulp, and hair follicles) along with stem cell therapy for over 80 approved disorders. The company also offers DCGI-approved REEPLASTY treatment for knee osteoarthritis, the patented Golden Vial anti-ageing program, and epigenetic biological age testing.
Is Ree Labs a public or private company?
Ree Labs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Ree Labs founded?
Ree Labs was founded in 2009. It employs 101 to 250 people.
Where is Ree Labs based?
Ree Labs is headquartered in Mumbai, India, in the Asia region.
How does Ree Labs make money?
Five revenue lines are on record. Stem Cell Banking Services are the primary driver. The others are stem Cell Therapy Services, golden Vial Anti-Ageing Program, biological Age Testing and baby Registry Gifting Platform.
Who are Ree Labs's main competitors?
Direct peers on record are LifeCell International, Cryo-Cell International, ViaCord, Cryoviva India, Medipost and CordLife. Emerging players are Novadip Biosciences, Stempeutics Research and Mesoblast. Global Cord Blood Corporation is listed as a regional player.
Does Ree Labs have an API?
No public API is recorded for Ree Labs.
What industry is Ree Labs in?
Ree Labs's product category is Stem Cell Banking Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 621991 and its SIC code is 2836.